Attovia Therapeutics receives bullish Wall Street coverage
Citi, Morgan Stanley, and RBC Capital Markets each initiated coverage of Attovia Therapeutics this week. Citi assigned a Buy/High Risk rating with a $30 price target, Morgan Stanley started the stock at Overweight with a $39 target, and RBC initiated coverage at Outperform with a $45 target. The shares were trading between $20.70 and $21.46 when the reports were released, indicating substantial upside potential under each analyst’s target.
The coverage is driven primarily by early clinical data for the company’s lead chronic‑itch candidate, ATTO‑1310, an experimental antibody that blocks the IL‑31 ligand, a validated pathway in chronic pruritus. ATTO‑1310 is built on Attovia’s ATTOBODY platform, which uses biparatopic antibody fragments that can be configured into single‑, dual‑, or multi‑target biologics, allowing the firm to target multiple immune‑mediated diseases with the same technology.
In Phase 1b studies, 65% of patients receiving ATTO‑1310 achieved at least a four‑point improvement on the Peak Pruritus Numerical Rating Scale at week four, compared with 11% on placebo. In a high‑itch atopic dermatitis cohort, 44% achieved the same threshold versus 25% for placebo. Citi noted that statistical significance in chronic pruritus was observed as early as week two. The drug also demonstrated durability, with free IL‑31 remaining suppressed for at least 12 weeks after a single dose, supporting the prospect of once‑quarterly maintenance dosing.
Safety data to date appear favorable: adverse events have been predominantly mild‑to‑moderate, with no treatment‑related serious or severe events reported and no detectable neutralizing anti‑drug antibodies. Analysts cautioned that the Phase 1b cohorts were small and exploratory, and that larger trials must confirm the durability and magnitude of the effect.
The optimism is reinforced by commercial validation of the IL‑31 pathway. Competing therapy Nemluvio, which targets the IL‑31 receptor, has generated an approximately $1 billion early‑revenue run‑rate, while Citi cited roughly $450 million in its first full year after launch and peak‑sales estimates of about $4 billion. Analysts believe the market could accommodate multiple IL‑31 therapies if Attovia can demonstrate efficacy or dosing advantages.
Morgan Stanley is particularly constructive on ATTO‑2306, modeling roughly $500 million of revenue, while RBC sees potential for more than $2 billion in worldwide peak sales for that program. RBC added that combining two validated pathways could deliver a “best of both worlds” profile for itch and skin lesions, although competition in atopic dermatitis is intensifying.
Financially, Citi estimates that Attovia will have pro‑forma cash of about $420 million following its upsized IPO, providing a runway into 2030 and allowing the company to reach several major clinical milestones without immediate additional capital. The company reported approximately $115 million in cash, cash equivalents, and marketable securities at June 30, prior to the IPO proceeds.
Despite the bullish ratings, analysts emphasized that Attovia remains a clinical‑stage, pre‑revenue biotechnology company. Key risks highlighted include failure to replicate early efficacy in larger trials, unexpected safety or immunogenicity signals, regulatory setbacks, manufacturing challenges, intensifying competition, and the possibility that the chronic‑itch market proves smaller than anticipated. RBC also noted that the initial ATTO‑1310 data derived from relatively small patient groups, and that the more complex ATTO‑2306 and ATTO‑1091 programs are still pre‑clinical.